NRX Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.4MTTM through 30 Jun 2026
Net Income -$23.5MTTM through 30 Jun 2026
Free Cash Flow -$19.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -580.2% |
| Operating Margin | -440.0% |
| Net Margin | -691.8% |
Returns
-68.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.27x
Net Debt-$6.7Mnet cash position
Cash & Equivalents$26.7M
Quality Metrics
Altman Z-Score-12.79
Piotroski F-Score3 / 9
FCF Margin-582.9%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $1.2M
Diluted EPSFY2025: $-1.34
Dividend
No dividend
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| HOPE Clinics | $1.1M | View detailsExpectations for continued growth as clinics integrate and expand services. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.